慢性粒细胞白血病治疗新药及耐药检测的研究进展
摘要
慢性粒细胞白血病(CML)发病机制较为明确,对其癌蛋白BCR-ABL的研究也较为透彻,因而常被作为肿瘤分子靶向治疗的研究模型。现就CML治疗新药研究进展及BCR-ABL基因检测技术进行综述。
出处
《国际检验医学杂志》
CAS
2008年第6期527-529,共3页
International Journal of Laboratory Medicine
参考文献15
-
1Peggs K. Imatinib mesylate-gold standards and silver linings [J]. Clin Exp Med, 2004, 4(1): 1-9.
-
2Shah NP. Loss of response to imatinib., mechanisms and management [J]. Hematology Am Soc Hematol Educ Program, 2005, 183 187.
-
3Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second gener ation inhibitors of BCR-ABL for the treatment of imatinib-resist ant chronic myeloid leukaemia [J]. Nat Rev Cancer, 2007, 7(5): 345-356.
-
4Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALI. [J]. N Engl J Med, 2006, 354(24) :2 542-2 551.
-
5Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase [J]. Blood, 2007, 109(10): 4 143-4 150.
-
6Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure [J]. Blood, 2007, 109(2): 497-499.
-
7Yokota A, Kimura S, Masuda S, et al. INNO-406, a novel BCRABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity [J]. Blood, 2007, 109(1) : 306-314.
-
8Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance [J]. Proc Natl Acad Sci USA, 2005, 102(6): 1 992-1 997.
-
9Giles FJ, Cortes J, Jones D, et al. MK 0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation [J]. Blood, 2007, 109(2): 500-502.
-
10Szych CM, Liesveld JL, Iqbal MA, et al. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec) resistant patients [J]. CancerGenet Cytogenet, 2007, 174(2): 132-137.
-
1李子明,陆舜,廖美琳.肿瘤的靶向治疗[J].国外医学（肿瘤学分册）,2005,32(12):905-909. 被引量：4
-
2魏辉.急性白血病研究热点：第56届美国血液学会年会报道[J].白血病．淋巴瘤,2014,23(12):705-706. 被引量：2
-
3刘兆董,江忠清,戴丽玉.宫颈癌微转移研究进展[J].国际检验医学杂志,2008,29(6):525-527. 被引量：4
-
4王瑜敏,陶志华.人乳头瘤病毒和前列腺癌的关系研究进展[J].国际检验医学杂志,2009,30(1):49-50. 被引量：1
-
5王庆国,李玉强,滕晓梅,王燕青.血清α_1-抗胰蛋白酶测定对原发性肝癌诊断及疗效观察的临床价值[J].国际检验医学杂志,2008,29(9):841-841. 被引量：6
-
6苏赞瑞,黄运福,陈璇.微小肝癌诊断的相关研究进展[J].右江民族医学院学报,2015,37(6):858-861. 被引量：2
-
7钟良清.ER、PR、HER-2和耐药检测在子宫内膜样腺癌中的表达及意义[J].现代保健（医学创新研究）,2007(02Z):3-4.
-
8江梅.非霍奇金淋巴瘤中D-二聚体相关性分析[J].国际检验医学杂志,2009,30(5):492-492. 被引量：2
-
9刘诚明,段新华.人肺腺癌多药耐药细胞系的建立及其生物学性状的测定[J].新疆医科大学学报,2005,28(6):540-542. 被引量：1
-
10宋丽华,宋现让.乳腺癌治疗新药Herceptin[J].国外医学（肿瘤学分册）,2002,29(1):39-43. 被引量：16
